Completed PHASE1 INTERVENTIONAL 1-arm NCT05989997

Phase I Clinical Trial of 68Ga-NOTA-SNA002

Phase I Clinical Trial of Evaluating 68Ga-NOTA-SNA002 for the Safety Tolerance, Radiation Absorbed Dose and Dosimetry in Patients With Solid Tumor

Sponsor: SmartNuclide Biopharma

Conditions Positron-Emission Tomography(PET) Solid Tumor

Interventions 68Ga-NOTA-SNA002

Updated 7 times since 2023 Last updated: Sep 9, 2025 Started: Nov 1, 2023 Primary completion: Nov 8, 2024 Completion: Nov 8, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05989997, this PHASE1 trial focuses on Positron-Emission Tomography(PET) and Solid Tumor and remains completed. Sponsored by SmartNuclide Biopharma, it has been updated 7 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Oct 2025 — Present [monthly]

Completed PHASE1
Jul 2025 — Oct 2025 [monthly]

Completed PHASE1
Nov 2024 — Jul 2025 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1

▶ Show 2 earlier versions

Jan 2024 — Jul 2024 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Sep 2023 — Jan 2024 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

SmartNuclide Biopharma

Data source: SmartNuclide Biopharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China